Intramuscular Injection Of Monoclonal Antibodies Simplifies Covid Treatment

Until effective and accessible SARS-CoV-2 antivirals are available, monoclonal antibodies remain our strongest treatment and prophylactic against Covid-19. These antibodies are typically administered by a drip, which often requires medical assistance. One antibody, however, sotrovimab, could be administered intramuscularly (by shot), making delivery of the treatment far simpler. Here we review a press release by sotrovimab producers GSK and VIR that details the intramuscular administration of sotrovimab.

The trial to test sotrovimab was a phase 3, randomized, double-blind, placebo-controlled study, which is the standard for an efficacy test of this nature. The aim of the trial was to determine whether intramuscular administration of the antibody was similarly effective to intravenous (IV) administration for the early treatment of mild-to-moderate Covid-19 in high-risk populations.

Read the full article on Forbes.

© William A. Haseltine, PhD. All Rights Reserved.